Anti-CEACAM5 (clone huMAb2-2)-SPDB-DM4 ADC

  • 1.00 Dollar US$
  • Published date: November 23, 2017
    • Shirley, New York, United States

This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-2) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM4 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.

Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells."

Result 0 votes
Jerry Carter
1 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • 5-Bromoindole


    Drug Development Shirley (New York) February 13, 2020 Check with publisher

    5-Bromoindole is a GSK-3 inhibitor.

  • FM19G11


    Drug Development Shirley (New York) February 13, 2020 Check with publisher

    FM19G11 is a hypoxia inducible factors α (HIFα) inhibitor. It has been reported to inhibit transcriptional activity of pluripotency markers (Sox2 and Oct4) in rodent and human stem cells under hypoxic conditions.

  • D-3


    Drug Development Shirley (New York) February 13, 2020 Check with publisher

    D-3 is a peptide exhibits toxicity in cultured iPSCs and ESCs after 1h of incubation.